E. C. Quant

1.2k citations

25 papers · 871 indexed · h-index 14

Impact in

Genetics top 2%
- Glioma Diagnosis and Treatment
Neurology top 5%
- Facial Nerve Paralysis Treatment and Research
- Vascular Malformations Diagnosis and Treatment

Papers in ⓘ

Genetics 17
- Glioma Diagnosis and Treatment 17
Internal Medicine 2

Co-authors: Patrick Y. Wen (18 shared papers)Jan Drappatz (14 shared papers)Andrew D. Norden (14 shared papers)Rameen Beroukhim (8 shared papers)Lisa Doherty (9 shared papers)A. S. Ciampa (9 shared papers)Debra C. LaFrankie (3 shared papers)Santosh Kesari (2 shared papers)
Journals: Journal of Clinical Oncology (8 papers)Journal of Neuro-Oncology (3 papers)Neuro-Oncology (3 papers)Current Oncology Reports (2 papers)Cancer (1 paper)
Partner nations: United States Canada

In The Last Decade

E. C. Quant

25 papers receiving 847 citations

Peers

Countries citing papers authored by E. C. Quant

Since Specialization

Citations

This map shows the geographic impact of E. C. Quant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. C. Quant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. C. Quant more than expected).

Fields of papers citing papers by E. C. Quant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. C. Quant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. C. Quant. The network helps show where E. C. Quant may publish in the future.

Co-authors

The 25 scholars most cited alongside E. C. Quant, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with E. C. Quant Line = papers co-authored together E. C. Quant links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab Neuro-Oncology ·E. C. Quant, Andrew D. Norden, Jan Drappatz, Alona Muzikansky, Lisa Doherty, Debra C. LaFrankie, A. S. Ciampa, Santosh Kesari, Patrick Y. Wen	2009	141
2	Medical therapies for meningiomas Journal of Neuro-Oncology ·Patrick Y. Wen, E. C. Quant, Jan Drappatz, Rameen Beroukhim, Andrew D. Norden	2010	121
3	The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta-analysis BMJ ·E. C. Quant, Shafali Jeste, Rajeev H. Muni, Alison Cape, Manveen K. Bhussar, Anton Y. Peleg	2009	94
4	Response Assessment in Neuro-Oncology Current Oncology Reports ·E. C. Quant, Patrick Y. Wen	2010	85
5	Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients Journal of Neuro-Oncology ·Andrew D. Norden, J. R. Di Bartolomeo, Shota Tanaka, Jan Drappatz, A. S. Ciampa, Lisa Doherty, Debra C. LaFrankie, Sandra Ruland, E. C. Quant, Rameen Beroukhim, Patrick Y. Wen	2011	71
6	Transcript Map of the 8p23 Putative Tumor Suppressor Region Genomics ·Paul C. Sun, Ravindra Uppaluri, Amy P. Schmidt, Mary E. Pashia, E. C. Quant, John B. Sunwoo, Susanne M. Gollin, Steven B. Scholnick	2001	64
7	Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure Journal of Neuro-Oncology ·Christine Lu‐Emerson, Andrew D. Norden, Jan Drappatz, E. C. Quant, Rameen Beroukhim, A. S. Ciampa, Lisa Doherty, Debra C. LaFrankie, Sandra Ruland, Patrick Y. Wen	2010	54
8	Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors Neuro-Oncology ·Brian J. Scott, E. C. Quant, Margaret B. McNamara, Peter Ryg, Tracy T. Batchelor, Patrick Y Wen	2010	51
9	Response Assessment Challenges in Clinical Trials of Gliomas Current Oncology Reports ·Patrick Y. Wen, Andrew D. Norden, Jan Drappatz, E. C. Quant	2010	30
10	Salvage stereotactic radiosurgery for breast cancer brain metastases Cancer ·Paul J. Kelly, Nancy U. Lin, Elizabeth B. Claus, E. C. Quant, Stephanie E. Weiss, Brian M. Alexander	2011	29
11	Recurrent High-Grade Glioma Current Treatment Options in Neurology ·E. C. Quant, Jan Drappatz, Patrick Y. Wen, Andrew D. Norden	2010	26
12	Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen Journal of Clinical Oncology ·E. C. Quant, Andrew D. Norden, Jan Drappatz, A. S. Ciampa, Lisa Doherty, D. C. LaFrankie, Santosh Kesari, Patrick Y. Wen	2008	25
13	AT-47 * PHASE I TRIAL OF INTRATHECAL TRASTUZUMAB IN HER2 POSITIVE LEPTOMENINGEAL METASTASES Neuro-Oncology ·Jeffrey J. Raizer, Elena Pentsova, Antonio Omuro, Nancy U. Lin, Lakshmi Nayak, E. C. Quant, P. Kumthekar	2014	14
14	Novel Medical Therapeutics in Glioblastomas, Including Targeted Molecular Therapies, Current and Future Clinical Trials Neuroimaging Clinics of North America ·E. C. Quant, Patrick Y. Wen	2010	14
15	Effects of cediranib, a VEGF signaling inhibitor, in combination with chemoradiation on tumor blood flow and survival in newly diagnosed glioblastoma. Journal of Clinical Oncology ·Elizabeth R. Gerstner, Kyrre E. Emblem, S. Andrew, April F. Eichler, Fred H. Hochberg, Jan Drappatz, E. C. Quant, Andrew D. Norden, Marco C. Pinho, Pavlina Polaskova, Dominique Jennings, Marek Ancukiewicz, S. Percy Ivy, Patrick Y. Wen, Rakesh K. Jain, A. Gregory Sorensen, Tracy T. Batchelor	2012	10
16	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Journal of Clinical Oncology ·Andrew D. Norden, Stephen T. Hammond, Jan Drappatz, Surasak Phuphanich, David A. Reardon, Eugene Hung Chih Wong, Scott R. Plotkin, G. J. Lesser, Jeffrey J. Raizer, Tracy T. Batchelor, E. C. Quant, Rameen Beroukhim, Thomas Kaley, Alona Muzikansky, A. S. Ciampa, Lisa Doherty, Kenneth Smith, M. Gérard, Christine Sceppa, Patrick Y. Wen	2011	10
17	Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology ·E. C. Quant, Tracy T. Batchelor, Andrew B. Lassman, David Schiff, Thomas Kaley, ET Wong, T. Mikkelsen, Jan Drappatz, Andrew D. Norden, Rameen Beroukhim, S. Weiss, Brian M. Alexander, Christine Sceppa, Mary Gerard, Stephen D. Hallisey, C. A. Bochacki, Kenneth Smith, Alona Muzikansky, Patrick Y. Wen	2011	8
18	Phase II study of dose-intense temozolomide in recurrent glioblastoma. Journal of Clinical Oncology ·Sue Hammond, Andrew D. Norden, G. J. Lesser, Jan Drappatz, Camilo E. Fadul, Tracy T. Batchelor, E. C. Quant, Rameen Beroukhim, Alona Muzikansky, A. S. Ciampa, Lisa Doherty, D. C. LaFrankie, Sandra Ruland, C. A. Bochacki, Katherine Griffin, Mary Gerard, Christine Sceppa, Myrna R. Rosenfeld, Patrick Y. Wen	2011	8
19	A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). Journal of Clinical Oncology ·Jan Drappatz, Jeffrey J. Raizer, David Schiff, A. S., Tracy T. Batchelor, Susan Snodgrass, E. C. Quant, Andrew D. Norden, Rameen Beroukhim, Sean Grimm, Lisa Doherty, A. S. Ciampa, D. C. LaFrankie, Sandra Ruland, Mary Gerard, Samantha N. Hammond, Patrick Y. Wen	2011	6
20	Safety of concurrent bevacizumab therapy and anticoagulation in high-grade glioma patients. Journal of Clinical Oncology ·J. R. Di Bartolomeo, Andrew D. Norden, Jan Drappatz, A. S. Ciampa, Lisa Doherty, D. C. LaFrankie, E. C. Quant, Rameen Beroukhim, Patrick Y. Wen	2010	3

About E. C. Quant

E. C. Quant is a scholar working on Genetics, Internal Medicine, Neurology, Cancer Research and Oncology, having authored 25 papers that have together received 871 indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (17 papers), Cancer Treatment and Pharmacology (6 papers), Brain Metastases and Treatment (6 papers), Cancer, Hypoxia, and Metabolism (5 papers), Meningioma and schwannoma management (4 papers), Histone Deacetylase Inhibitors Research (4 papers), Vascular Malformations Diagnosis and Treatment (3 papers) and Pituitary Gland Disorders and Treatments (2 papers). The work is most often cited by research in Genetics (494 citations), Neurology (261 citations), Cancer Research (171 citations), Otorhinolaryngology (43 citations) and Pulmonary and Respiratory Medicine (226 citations). E. C. Quant has collaborated with scholars based in United States and Canada. Frequent co-authors include Patrick Y. Wen, Jan Drappatz, Andrew D. Norden, Rameen Beroukhim, Lisa Doherty, A. S. Ciampa, Debra C. LaFrankie, Santosh Kesari, Alona Muzikansky and Shafali Jeste. Their work appears in journals such as Journal of Clinical Oncology, Journal of Neuro-Oncology, Neuro-Oncology, Current Oncology Reports and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact